[Use of corticosteroids after esophageal dilations on patients with corrosive stenosis: prospective, randomized and double-blind study].
OBJECTIVE
To determine triancinolone intralesional injections effects in association with esophageal dilations in corrosive stenosis cases, by means of a double-blind and randomized study.


METHODS
Fourteen adults patients (6 men and 8 women) with severe esophageal corrosive stenosis were randomized in two groups: Group A: treated by esophageal dilations and posterior triancinolone 10 mg/ml intralesional injection; Group B: treated by esophageal injections and posterior saline solution 0,9% injection (placebo). New applications were made based on the patient symptomatology. It had been analysed dilation frequency, obtained diameters and dysphagia before and after the research, for 12 months.


RESULTS
Eleven patients had ingested sodium hydroxide, two had ingested ammoniac and one had taken muriatic acid. There was no statistic difference (p > 0.05) in dilation frequency and dysphagia between the groups. However, an improvement in obtained diameter was observed in the corticosteroids group in comparison with control group (p < 0.05). By comparing groups before and after steroids, the final results were very favorable in group A CONCLUSION: Multiple intralesional injections of triancinolone hexacetonide 10 mg/ml in association with esophageal dilations increase obtained diameters in succeeding sessions.
Camargo
Marcelo Amade
MA
Departamento de Moléstias do Aparelho Digestivo Gastrocentro - Faculdade de Ciências Médicas, Universidade Estadual de Campinas, SP, Brasil.
Lopes
Luiz Roberto
LR
Grangeia
Tiago de Araújo Guerra
Tde A
Andreollo
Nelson Adami
NA
Brandalise
Nelson Ary
NA
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D002057:Burns, Chemical / Q000150:complications*; D003131:Combined Modality Therapy; D004106:Dilatation / Q000379:methods; D004311:Double-Blind Method; D004940:Esophageal Stenosis / Q000139:chemically induced / Q000188:drug therapy*; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000031:analogs & derivatives*
D000893:Anti-Inflammatory Agents; D014222:Triamcinolone Acetonide; C005900:triamcinolone hexacetonide